Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

ABSTRACT:

SUBMITTER: Haas NB 

PROVIDER: S-EPMC4878938 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature